- |||||||||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal: Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia. (Pubmed Central) - Jan 27, 2023
High rates of successful switching to LAI aripiprazole from other antipsychotics suggest its good tolerability and effectiveness. Improvements in psychopathology and social functioning were more evident in patients with recent- onset schizophrenia, and improvements in metabolic abnormalities were more prominent in patients with chronic schizophrenia.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia. (Pubmed Central) - Jan 27, 2023
Continuous 3-monthly paliperidone palmitate treatment significantly enhances the personal and social performance of patients with schizophrenia and reduces the proportion of those with severe illness. These findings suggest that long-acting injectable antipsychotic administration at intervals longer than 1 month might improve the social functioning of and promote return to activities of daily living in patients with schizophrenia.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical, Journal: Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation. (Pubmed Central) - Nov 22, 2022
Increased psychopathology severity was associated with an increased likelihood of relapse, while having a job or being in school was protective. These findings reinforce the necessity of conducting research in patients with comorbid psychiatric disorders who are typically underrepresented in RCTs, yet overrepresented in real-life settings, in order to better inform and guide clinical practice.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal, HEOR: Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate. (Pubmed Central) - Nov 16, 2022
Ms Morrison, Ms Ghelerter, Ms Vermette-Laforme, Mr Lefebvre, and Mr Pilon are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Scientific Affairs, LLC., which funded the development and conduct of this study and manuscript. Dr Lin and Ms Benson are employees of Janssen Scientific Affairs, LLC., and stockholders of Johnson & Johnson.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Reimbursement, Retrospective data, Journal, Real-world evidence, Medicaid: Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation. (Pubmed Central) - Nov 10, 2022
Dr Lin and Ms Benson are employees of Janssen Scientific Affairs, LLC., and stockholders of Johnson & Johnson. This real-world investigation of adult Medicaid members with schizophrenia or schizoaffective disorder observed improved adherence and persistence with fewer readmissions with PP1M/PP3Ms versus OAP-switches.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal: Microcrystals of Ketal-Linked Paliperidone Prodrugs for Long-Acting Antipsychotics. (Pubmed Central) - Nov 9, 2022
We found that paliperidone exposure in SKP-MC-treated rats was prolonged compared with that in rats treated with the commercial antipsychotic Invega Sustenna and that the drug release rate decreased with increasing MC size...Our findings will provide valuable insights into in vivo drug release from prodrug-based MC formulations. The ketal-linked prodrug strategy might be a new solution for developing long-acting prodrug formulations of hydroxyl-group-bearing drugs.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Alternative initiations of 3-monthly paliperidone palmitate. A retrospective study (Poster area [ONLINE]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_1237;
In this descriptive study we present a sample of patients with severe mental disorder with a complex course who responded excellently to 3-monthly paliperidone palmitate directly with oral supplementation for 45 days or with an initial dose of paliperidone palmitate monthly followed by direct maintenance with 3-monthly paliperidone palmitate, without the need for a 4-month wait with the monthly paliperidone palmitate regimen. This reduction in time to reach the 3-monthly LAIA regimen could be related to the excellent efficacy, tolerability and adherence observed in the present study.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
First clinical experiences with 6-monthly paliperidone palmitate – A retrospective study (Poster area [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_1030;
In the present study, the use of said LAIA in a group of 20 patients is objectified, showing excellent efficacy and tolerability. All study patients were already stable with the 1-monthly and 3-monthly paliperidone palmitate formulations, maintaining said psychopathological stability when switching to the 6-monthly paliperidone palmitate formulation, with excellent adherence and adverse effect profile .
- |||||||||| aripiprazole / Generic mfg.
Depot aripiprazole versus paliperidone in dual disorder patients – an observational study (Poster area [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_942;
We compared three treatment lines: monthly aripiprazole, monthly paliperidone and three month paliperidone. Methods : We conducted an open observational study with a sample of 265 patients from A Coruña (Spain)...We observe also that paliperidone was often used in more severe patients..Side effects were observed more often with paliperidone, but the number of them was relatively low with both treatment lines. We also observed that the abstinence rate was about 80% and adherence rates overcame 90%, indicating that the greatest part of the patients observed at least some grade of improvement that made them stay in the program.In Conclusion , both drugs seemed to be effective on treating dual disorder patients, with a more favourable side effect profile for aripiprazole.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Efficacy and safety of paliperidone palmitate 6-month versus paliperidone palmitate 3-month long-acting injectable in patients with schizophrenia in Europe (Poster area [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_828;
P3
The Result s of this sub-group analysis were consistent with the findings of global study [4]. Conclusion : PP6M demonstrated non-inferior efficacy to PP3M in patients with schizophrenia in Europe, as observed in the global study. Safety Result s for PP6M were consistent with the known profile of paliperidone and were indistinguishable from the safety profile of PP3M.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Hyperprolactinemia associated with paliperidone palmitate treatment (Poster area [IN-PERSON]) - Oct 13, 2022 - Abstract #ECNP2022ECNP_748;
Conclusion : - It is observed that PRL monitoring is not common in our health area, and the recommendations of the CPGs are not followed or at least, they are not reflected in the EMR.-The use of PP1M/PP3M concomitantly with oral aripiprazole does not turn out to be a very widespread therapeutic option. This association is not always justified by hyperprolactinemia.- The therapeutic controversy over iatrogenic hyperprolactinemia due to antipsychotics may be reflected in the study population.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Journal: Baseline risk characterization of early versus later adopters of long-acting paliperidone palmitate formulations. (Pubmed Central) - Sep 30, 2022
In the United States, the baseline characteristics of early adopters of PP1M and PP3M did not suggest higher mortality risk than later adopters. These results offer no convincing evidence that the unconfirmed early signal of increased mortality with PP1M was due to increased baseline mortality risk among early adopters.
- |||||||||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Trial completion date, Trial primary completion date: Substance Misuse To Psychosis for Stimulants (clinicaltrials.gov) - Sep 7, 2022
P2/3, N=240, Recruiting,
These results offer no convincing evidence that the unconfirmed early signal of increased mortality with PP1M was due to increased baseline mortality risk among early adopters. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: May 2022 --> May 2023
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Clinical, PK/PD data, Journal: Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics (Pubmed Central) - Jul 1, 2022
Currently in Greece, two first-generation (haloperidol and zuclopenthixol) and four newer LAIs (risperidone, olanzapine, paliperidone and aripiprazole) are in circulation...Furthermore, risperidone is the only LAI administered every 2 weeks and 3-monthly paliperidone is the only one administered every 3 months...This paper reviews the pharmacokinetic and pharmaceutical characteristics of these drugs. It also provides information concerning basic elements of LAI pharmacokinetics in order to understand these characteristics better.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal: Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020. (Pubmed Central) - Jun 23, 2022
For example, there was a 3 to 4-fold increase in the prices of haloperidol, chlorpromazine, fluphenazine, trifluperazine and zuclopenthixol, while a less than two-fold increase in pimozide, flupenthixol, sulpiride, amisulpride and quetiapine and a decrease in the prices of clozapine, olanzapine, ziprasidone and risperidone in the tablet form...Consta 25, 37.5, 50 LAI 37.5/1 444.17 11.840 1/15* 29.61 10,807 5,402 16 Paliperidone Invega 3, 6, 9 tb 6/28 213.15 1.268 6 7.61 2,777 - Xeplion 50, 75, 100, 150 LAI 100/1 1161.56 11.615 1/30* 38.72 14,132 - Trevicta 175, 263, 350, 525 LAI 350/1 3426.95 9.788 1/90* 38.08 13,899 - 17 Aripiprazole Abilify 5, 10, 15, 20 tb; 1 sol 20/28 113.25 0.404 20 8.08 2,949 - Abilify Main...Table 2. Comparison of the Annual Costs of Antipsychotic Drugs Calculated By The Daily Standard Average Dose Use, at Certain Price Ranges, for the Years 2005 and 2020 Price bracket (TRY) 2005 2020 500 ↓ Haloperidol tb, amp, Trifluoperazine drj, Chlorpromazine tb, Pimozid tb, Fluphenazine LAI Haloperidol tb, amp, depo, Trifluoperazine drj, Pimozid tb 500-1,000 Flupenthixol drj, LAI, Zuklopenthixol tb, acu, LAI, Sulpirid tb Chlorpromazine tb, Fluphenazine LAI, Flupenthixol drj, LAI, Clozapine tb, Risperidone tb 1,000-2,000 Clozapine tb, Risperidone tb Olanzapine tb, Sulpirid tb 2,000-3,000 Amisulpirid tb, Olanzapine tb, Quetiapine tb Zuklopenthixol tb, acu, LAI, Amisulpirid tb, Ziprasidone tb, Paliperidone tb, Aripiprazole tb 3,000-5,000 Ziprasidone tb Quetiapine tb 5,000-10,000 Risperidone consta Sertindole tb 10,000 ↑ Risperidone consta, Paliperidone monthly, Paliperidone 3 monthly, Aripiprazole maintana tb: Tablet, drj: Dragee, amp: Ampoule, LAI: Long-acting injectable, acu: Acuphase.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J
Trial completion: A Study of Paliperidone Palmitate 6-Month Formulation (clinicaltrials.gov) - Jun 22, 2022
P3, N=178, Completed,
Comparison of the Annual Costs of Antipsychotic Drugs Calculated By The Daily Standard Average Dose Use, at Certain Price Ranges, for the Years 2005 and 2020 Price bracket (TRY) 2005 2020 500 ↓ Haloperidol tb, amp, Trifluoperazine drj, Chlorpromazine tb, Pimozid tb, Fluphenazine LAI Haloperidol tb, amp, depo, Trifluoperazine drj, Pimozid tb 500-1,000 Flupenthixol drj, LAI, Zuklopenthixol tb, acu, LAI, Sulpirid tb Chlorpromazine tb, Fluphenazine LAI, Flupenthixol drj, LAI, Clozapine tb, Risperidone tb 1,000-2,000 Clozapine tb, Risperidone tb Olanzapine tb, Sulpirid tb 2,000-3,000 Amisulpirid tb, Olanzapine tb, Quetiapine tb Zuklopenthixol tb, acu, LAI, Amisulpirid tb, Ziprasidone tb, Paliperidone tb, Aripiprazole tb 3,000-5,000 Ziprasidone tb Quetiapine tb 5,000-10,000 Risperidone consta Sertindole tb 10,000 ↑ Risperidone consta, Paliperidone monthly, Paliperidone 3 monthly, Aripiprazole maintana tb: Tablet, drj: Dragee, amp: Ampoule, LAI: Long-acting injectable, acu: Acuphase. Active, not recruiting --> Completed
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal: Poroptosis: A form of cell death depending on plasma membrane nanopores formation. (Pubmed Central) - Jun 22, 2022
Here, we reveal that ppM1 peptide is capable of forming irreparable transmembrane pores on tumor cell membrane, leading to ICD which we name poroptosis...Our results suggested that steady transmembrane-nanopore-mediated subacute cell death played a vital role in subsequent activated immunity that transforms to an antitumor immune microenvironment. Selectively generating poroptosis in cancer cell could be a promise strategy for cancer therapy.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal: LGR5-Expressing Cells in the Healing Process of Post-ESD Ulcers in Gastric Corpus. (Pubmed Central) - Jun 9, 2022
LGR5 expression appears to contribute to mucosal regeneration in the human gastric corpus. The application of LGR5 expression analysis to mucosal regeneration and fundic gland-type gastric tumors is expected.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Preclinical, Journal: Comparison of Paliperidone Palmitate from Different Crystallization Processes and Effect on Formulations In Vitro and In Vivo. (Pubmed Central) - May 30, 2022
Meanwhile, pharmacokinetic in vivo results demonstrated that the pharmacokinetic profiles and parameters of formulation containing PP-2 and Invega Sustenna tended to be consistent, but those of formulations containing PP-1 were significantly different from those of formulations containing PP-2 or Invega Sustenna, and there was burst release phenomenon of formulations containing PP-1 in rats. PP made by different crystallization processes could induce changes in appearance, SFE, and crystallinity, and further affect the stability, state, and pharmacokinetic in vivo formulation.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Observational data, Retrospective data, Journal, Real-world evidence: Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain. (Pubmed Central) - May 18, 2022
PP made by different crystallization processes could induce changes in appearance, SFE, and crystallinity, and further affect the stability, state, and pharmacokinetic in vivo formulation. PP3M was more effective than OAs and monthly LAIs in improving clinical outcomes for patients with schizophrenia in a real-world setting in Spain.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Budget Impact of Introducing Once-Every-Six-Months Paliperidone Palmitate for the Management of Schizophrenia Among Medicaid Beneficiaries in Georgia () - May 5, 2022 - Abstract #APA2022APA_842;
Introducing PP6M to the GA Medicaid program for managing adults with schizophrenia who are currently stabilized on PP1M or PP3M is projected to have a low impact on the state budget over 5 years. Modeling the impact of PP6M to the Medicaid budget of a state, like GA, can help policy makers with formulary decisions aimed at improving medication adherence and optimizing outcomes for beneficiaries with schizophrenia.
- |||||||||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, Lundbeck, Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
High Doses of Second-Generation Long-Acting Antipsychotics in Patients With Severe Resistant Schizophrenia. a Six-Year Mirror-Image Study () - May 5, 2022 - Abstract #APA2022APA_753;
Conclusions Risperidone LAI, Paliperidone Palmitate and Aripiprazol once-monthly, at high doses, improved treatment adherence and outcomes (hospitalizations, suicide attempts, clinical severity, disability) of patients with severe resistant schizophrenia, with good tolerability, helping them to achieve clinical stabilization and better functioning. Therefore, we suggest that, in some illness critical conditions, high doses of SGA LAIs could represent an alternative to clozapine.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Journal: How Loading Dose Strategies for Depot Paliperidone Can Go Wrong. (Pubmed Central) - Apr 28, 2022
This column presents a real-life case of a patient who developed severe and prolonged Parkinsonism secondary to the loading dose strategy recommended in the prescribing information (package insert) for paliperidone palmitate (Invega Sustenna)...To put this case in context, a review of the literature was conducted which identified 3 related cases. The author also refers readers to previous articles on therapeutic drug monitoring and pharmacokinetic considerations that arise when using depot (long-acting injectable) antipsychotics.
|
